Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
Public ClinicalTrials.gov record NCT01467492. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Phase 4 Study of Telaprevir, Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C Who Have Not Achieved a Sustained Viral Response With a Prior Course of Interferon-Based Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in treatment-experienced Black/African American and non-Black/African American participants with Genotype 1 Chronic Hepatitis C (CHC), who have not achieved a sustained viral response with a prior course of interferon-based therapy.
Study identification
- NCT ID
- NCT01467492
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 121 participants
Conditions and interventions
Conditions
Interventions
- Telaprevir Drug
- Ribavirin Drug
- Pegylated Interferon Alfa-2a Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2012 (Type not available)
- Primary completion
- May 2014 (Actual)
- Completion
- May 2014 (Actual)
- Last update posted
- Aug 3, 2015
2012 – 2014
United States locations
- U.S. sites
- 27
- U.S. states
- 18
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama | Birmingham | Alabama | — | — |
| California | San Francisco | California | — | — |
| Connecticut | New Haven | Connecticut | — | — |
| Washington, DC | Washington D.C. | District of Columbia | — | — |
| Florida | Miami | Florida | — | — |
| Florida | Orlando | Florida | — | — |
| Florida | Tampa | Florida | — | — |
| Florida | West Palm Beach | Florida | — | — |
| Georgia | Atlanta | Georgia | — | — |
| Illinois | Chicago | Illinois | — | — |
| Louisiana | Baton Rouge | Louisiana | — | — |
| Louisiana | New Orleans | Louisiana | — | — |
| Louisiana | Shreveport | Louisiana | — | — |
| Maryland | Baltimore | Maryland | — | — |
| Massachusetts | Boston | Massachusetts | — | — |
| Michigan | Detroit | Michigan | — | — |
| New Jersey | Vineland | New Jersey | — | — |
| New York | New York | New York | — | — |
| New York | The Bronx | New York | — | — |
| North Carolina | Charlotte | North Carolina | — | — |
| North Carolina | Durham | North Carolina | — | — |
| Pennsylvania | Philadelphia | Pennsylvania | — | — |
| Texas | Dallas | Texas | — | — |
| Texas | Houston | Texas | — | — |
| Texas | San Antoinio | Texas | — | — |
| Virginia | Norfolk | Virginia | — | — |
| Washington | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01467492, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 3, 2015 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01467492 live on ClinicalTrials.gov.